INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patients with pulmonary arterial hypertension      │ Patients with pulmonary arterial hypertension      │     100 │
│ (PAH)                                              │ (PAH)                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with chronic thromboembolic pulmonary     │ Patients with chronic thromboembolic pulmonary     │     100 │
│ hypertension (CTEPH)                               │ hypertension (CTEPH)                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ All prevalent patients (diagnosed \>12 month ago)  │ All prevalent patients (diagnosed >12 month ago)   │     100 │
│ with PAH or distal CTEPH who had a consultation at │ with PAH or distal CTEPH who had a consultation at │         │
│ the PH centre in Zurich between November 2015 and  │ the PH centre in Zurich between November 2015 and  │         │
│ November 2016)                                     │ November 2016)                                     │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                 │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════════════╪═════════╡
│ -                                 │ Patients with pulmonary arterial hypertension │       0 │
│                                   │ (PAH)                                         │         │
├───────────────────────────────────┼───────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Patients with pulmonary arterial hypertension │      31 │
│                                   │ (PAH)                                         │         │
╘═══════════════════════════════════╧═══════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 94
Average Levenshtein Ratio of individual lines: 66.2
OverAll Ratio: 80.1
